HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +422%

  £407,416 → £2,126,785

• Net assets

  -13,005.5%

  -£13,456 → -£1,763,475

• Employees

  —

  Not reported

• Operating profit

  -216.4%

  -£530,014 → -£1,676,759

• Profit before tax

  -233.2%

  -£529,267 → -£1,763,475

• Wages

  +158.2%

  £368,543 → £951,633

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED 2018-10-19 → present
2. WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED 2011-09-14 → 2018-10-19
3. WEST-WARD (GB) LIMITED 2011-06-23 → 2011-09-14

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Company has net liabilities at 31 December 2024 of $2,359k (2023: net liabilities $18k). The Company has a letter of support in place from its ultimate parent company, Hikma, which states that, should it be required, Hikma will provide financial support to the Company for additional funding or to enable it to discharge its liabilities as they fall due for the foreseeable future. The Directors have assessed the ability of Hikma to provide that support and, on that basis, have concluded that the application of the going concern basis of preparation of the financial statements is appropriate.”

Group structure

1. HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED · parent
   1. Hikma d.o.o. 100% · Croatia · R&D center
   2. Hikma Services India Private Limited 0.01% · India

Significant events

• “During the year, the Company opened Hikma Pharmaceuticals International Limited, London, Geneva Branch (the "Swiss Branch") to supervise the global manufacturing and distribution of certain pharmaceutical products...”
• “In September 2024, the Company acquired a new subsidiary, an R&D center located in Zagreb, Croatia, as part of the Group's acquisition of the Xellia business.”
• “While the Company became a holding company during the year, its primary activities continue to relate to the wholesale distribution of medicinal products in the United Kingdom.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.